Sharemaestro Newsreel

Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance

Pfizer (PFE) Q2 Earnings and Revenues Top Estimates

Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

Merck & Co., Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:MRK) 2026-08-04

Bristol Myers Squibb Company (BMY) Hit a 52 Week High, Can the Run Continue?

AstraZeneca Stock Drops 7% as Merger Talks With Bristol Myers Squibb Surface

Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026

Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

My AstraZeneca shares just crashed 9.7%! Here’s why I’m NOT selling

AstraZeneca shares dropped significantly due to rumors of a potential mega-merger with Bristol Myers Squibb and a failed late-stage trial for its heart disease program, Wainua. Despite these setbacks, an investor is not selling, viewing the decline as a market overreaction rather than a …

Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

The European Commission has approved an extension of the indication for Sanofi's MenQuadfi vaccine to include infants from six weeks of age, protecting against invasive meningococcal disease caused by serogroups A, C, W, and Y. This expanded approval, supported by the MET58 pivotal study, …

California Supreme Court Rules for Gilead, Says Drugmakers Don’t Have ‘Duty to Innovate’

The California Supreme Court ruled in favor of Gilead Sciences, stating that drug manufacturers of safe drugs do not have a "duty to innovate" and develop potentially safer alternatives. This decision dismisses negligence claims from 24,000 patients using an HIV drug from Gilead, reversing …

An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

Reports of a potential megamerger between AstraZeneca and Bristol Myers Squibb have been met with skepticism and a significant stock sell-off on Wall Street. Analysts are perplexed by AstraZeneca's interest, given its strong organic growth, while Bristol Myers faces patent expirations for key products. …

Bristol-Myers Squibb, AstraZeneca deal talks remain active - report

A recent report indicates that deal talks between AstraZeneca and Bristol-Myers Squibb are still ongoing. Following this news, Bristol-Myers Squibb's shares saw a slight increase, while AstraZeneca's shares experienced a minor decline. This update follows an earlier Financial Times report about potential acquisition discussions.

AstraZeneca and Bristol-Myers Squibb: Megamerger Reports Leave Us Scratching Our Heads

Morningstar reports on the potential megamerger between Bristol-Myers Squibb and AstraZeneca, noting that such large acquisitions are rare in biopharma. While the deal could combine complementary patent portfolios and pipeline assets, concerns exist regarding integration challenges and regulatory hurdles due to overlapping oncology focuses. …

Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S Revenue Breakdown – NEO:PFE

This article provides a revenue breakdown for Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S (NEO:PFE). It highlights that the United States was the primary contributor to the company's revenue, generating ‪51.81 billion CAD last year and ‪53.01 billion CAD …

Smart Money is Buying Eli Lilly & Co. (LLY)

Institutional investors, including prominent quantitative managers and hedge funds, significantly increased their positions in Eli Lilly & Co. (LLY) during the last reported quarter. Notable buyers like AQR Capital Management and Fisher Asset Management led the buying, underscoring strong confidence in Lilly's future growth, …

PRIVACY ALERT: Amgen Under Investigation for Data Breach of Records

Schubert Jonckheer & Kolbe are investigating a data breach at Amgen Inc. that compromised sensitive information, including proprietary data and patient protected health information, from its cloud storage systems in July 2026. Amgen disclosed the "material" breach in an SEC filing but has not …

Eli Lilly to offer early access to next-gen obesity drug to some patients

Eli Lilly announced it will offer early access to its experimental obesity drug, retatrutide, to a limited number of patients before its U.S. FDA approval. This expanded access program is for patients aged 18 or older with refractory obesity who meet specific medical criteria, …

Opinion | Gilead Beats the Plaintiff Bar

The California Supreme Court rejected a lawsuit against Gilead Sciences, providing a rare win for businesses against expansive liability theories. The suit, brought by 24,000 HIV patients, claimed Gilead delayed a new drug launch to maximize profits from an existing medicine. The court's decision …

July Social Media Round-Up—America 250, Pfizer Futures, and More

This article provides a round-up of Pfizer's social media activities in July, highlighting various discussions, achievements, and scientific insights. It covers topics like living with alopecia areata, a Pfizer colleague's cancer survival story, and reflections on scientific advancements. The summary also notes leadership updates, …

California Supreme Court sides with Gilead in ‘duty’ to innovate case

The California Supreme Court has ruled in favor of Gilead Sciences in a significant case concerning the company's development of HIV medications. The 6-1 decision overturned a previous appeals court ruling, which had suggested Gilead could be held liable for allegedly slow-walking the development …

Amgen Tells SEC Hack Exposed Patient Data, Trade Secrets

Amgen has informed the U.S. Securities and Exchange Commission (SEC) about a June data breach that may have compromised intellectual property, patient information, research and development data, and other confidential business files. The pharmaceutical giant discovered unauthorized activity in July within cloud environments hosted …

AbbVie’s Growth Now Leans On A Single Molecule

AbbVie's future growth is heavily reliant on a single drug, SKYRIZI, which is projected to account for close to one-third of the company's total revenue in 2026. While the patent for SKYRIZI extends well into the 2030s, the company faces a challenge with its …

Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger

Jim Cramer expressed skepticism regarding the rumored $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb, calling it a potential "fake out" and suggesting BMY needs assistance. The Financial Times reported ongoing discussions, which could lead to a cash and stock deal, combining AstraZeneca's …

Amgen Inc. stock underperforms Monday when compared to competitors

Amgen Inc. (AMGN) stock fell by 1.63% to $378.87 on Monday, underperforming the broader market. This occurred despite a generally favorable trading session where the S&P 500 Index rose 1.48% and the Dow Jones Industrial Average rose 1.32%. This marks the second consecutive day …

Merck & Co. Inc. stock underperforms Monday when compared to competitors

Merck & Co. Inc. (MRK) stock declined by 1.87% on Monday, closing at $127.77, despite a positive trading session for the broader market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains. Merck's stock finished 5.39% below its 52-week high …

Amarin Corporation (AMRN) CFO equity award includes tax share withholding

Amarin Corporation's SVP & CFO, Peter L. Fishman, reported equity compensation activity where 313 Restricted Stock Units vested and converted into American Depositary Shares (ADSs). To cover tax obligations, 155 ADSs were withheld by the company at $14.26 per share, a transaction noted as …

AbbVie Inc. stock underperforms Monday when compared to competitors

AbbVie Inc. (ABBV) stock fell 2.33% on Monday, closing at $245.10, despite a generally positive trading session where the S&P 500 and Dow Jones Industrial Average both saw gains. This marks the third consecutive day of losses for AbbVie, underperforming its competitors. The article …

Gilead wins California Supreme Court decision that it calls 'a victory for all' drug developers

Gilead Sciences Inc. has won a significant case at the California Supreme Court concerning its best-selling HIV drugs. The company views this decision as a victory not only for itself but also for all drug developers working on new and improved medical treatments. This …

California drugmaker Amgen reports theft of patient data in cyber incident

Amgen Inc., a California drugmaker, reported a cyber incident involving the theft of patient health information and proprietary data from third-party cloud servers in July. While the company is still assessing the full impact, it currently does not expect the breach to materially affect …

Amgen Reports Data Breach Exposes Protected Health Info

Amgen Inc. disclosed a data breach to the SEC on July 29, 2026, involving unauthorized access and exfiltration of data from third-party cloud environments. The exposed information includes proprietary company data and patient protected health information. Amgen states that there has been no identified …

Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Levi & Korsinsky LLP has announced a class action securities lawsuit against Merck & Co., Inc. (NYSE:MRK) for shareholders who suffered losses due to alleged securities fraud between February 3, 2022, and February 3, 2025. The lawsuit claims Merck misrepresented expected Gardasil sales, leading …

AbbVie Inc. 2026: Revenue $16.99B, EPS $2.03— 10-Q Summary

AbbVie Inc. reported its 2026 quarterly results, with revenue reaching $16.99 billion and diluted EPS at $2.03, marking significant growth over the prior year. This performance was attributed to strong sales of key brands like Skyrizi, Rinvoq, and neuroscience products, despite a decline in …

Form 144 BIOGEN INC. For: 3 August By Investing.com

This article from Investing.com is a brief announcement regarding a Form 144 filing for BIOGEN INC. on August 3rd. It provides no further details about the filing, serving primarily as a notification of its existence. The article also includes various market data, news headlines, …

FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto

The FDA has approved Novartis' Pluvicto for an earlier stage of metastatic hormone-sensitive prostate cancer, significantly expanding the eligible patient population. This approval is based on the Phase 3 PSMAddition study, which showed a substantial reduction in disease progression or death when Pluvicto was …

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

Eli Lilly and Company announced that the U.S. FDA has granted Breakthrough Therapy designation to olomorasib as a monotherapy for treating advanced pancreatic cancer in adults with a KRAS G12C mutation who have undergone at least one prior systemic therapy. This designation aims to …